Modulation of Prothrombinase Assembly and Activity by Phosphatidylethanolamine by Majumder, Rinku et al.
Modulation of Prothrombinase Assembly and Activity by
Phosphatidylethanolamine*
Received for publication, May 12, 2011, and in revised form, August 14, 2011 Published, JBC Papers in Press, August 22, 2011, DOI 10.1074/jbc.M111.260141
Rinku Majumder‡1, Xiaoe Liang§, Mary Ann Quinn-Allen§, William H. Kane§2, and Barry R. Lentz‡3
From the §Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27702-3656
and the ‡Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599-7260
Background: PS is an allosteric regulator lipid that appears on activated platelets along with PE.
Results:We show that PE 1) increases the kcat and decreases Km of thrombin formation; 2) reduces membrane surface packing
to promote Va binding; and 3) binds to Va and Xa to trigger their tight association.
Conclusion: This suggests a role in initiating blood coagulation.
Significance: PE may also be a regulator lipid.
Constituents of platelet membranes regulate the activity of
the prothrombinase complex. We demonstrate that mem-
branes containing phosphatidylcholine and phosphatidyletha-
nolamine (PE) bind factorVawith high affinity (Kd  10nM) in
the absence of phosphatidylserine (PS). These membranes sup-
port formation of a 60–70% functional prothrombinase com-
plex at saturating factor Va concentrations. Although reduced
interfacial packing does contribute to factor Va binding in the
absence of PS, it does not correlate with the enhanced activity of
the Xa-Va complex assembled on PE-containing membranes.
Instead, specific protein-PE interactions appear to contribute to
the effects of PE. In support of this, soluble C6PE binds to
recombinant factor Va2 (Kd  6.5 M) and to factor Xa (Kd 
91 M). C6PE and C6PS binding sites of factor Xa are specific,
distinct, and linked, because binding of one lipid enhances the
binding and activity effects of the other. C6PE triggers assembly
(Kdapp  40 nM) of a partially active prothrombinase complex
between factor Xa and factor Va2, compared withKdapp for C6PS
2 nM. These findings provide new insights into the possible
synergistic roles of platelet PE and PS in regulating thrombin
formation, particularly when exposed membrane PS may be
limiting.
Localization of blood coagulation enzymes and cofactors to
the surface of procoagulant anionic phospholipid membranes
is a central paradigm in hemostasis and thrombosis (1, 2). The
prototype for these complexes is the prothrombinase complex
that catalyzes the conversion of prothrombin to thrombin. This
enzyme complex consists of the enzyme factor Xa, the cofactor
factor Va, and calcium bound to a phospholipid surface. For-
mation of the prothrombinase complex results in a greater than
105-fold rate enhancement in the conversion of prothrombin to
thrombin (3, 4). Abnormal regulation of the prothrombinase
complex has been demonstrated to be critical in the pathogen-
esis of thrombotic disorders (5).
PS has long been considered the most important phospho-
lipid contributing to the activity of coagulation factors on phos-
pholipid membranes (6). Near optimal binding of Xa and Va to
model membranes occurs at 10–12% PS,4 which supports
optimal prothrombinase activity (7, 8). Membrane PE has been
shown to enhance prothrombin activation particularly in the
presence of low concentrations of PS (1–5%) (9). PE does not
affect prothrombin activation rates at optimal PS concentra-
tions but reduces the requirement for PS 10-fold (10). The
presence of PE in amembrane decreases theKmapp for prothrom-
bin, as well as the Kdapp for formation of the factor Va-factor Xa
complex (10). These authors hypothesized that the observed
effects on Km and Kdeff might result from reduced interfacial
packing generally associated with the presence of PE in a mem-
brane. In the current paper, we test this hypothesis and ask
whether there are additional effects of PE on membrane bind-
ing of factors Xa or Va or on the activity of factors Xa or Va that
might also contribute to the effects of PE on prothrombinase
activity and prothrombinase assembly.
EXPERIMENTAL PROCEDURES
Proteins and Reagents—Bovine and human coagulation pro-
teins, as well as the thrombin inhibitor dansylarginine-N-(3-
ethyl-1,5-pentanediyl) amide (DAPA), were obtained from
Hematologic Technologies, Inc. (Essex Junction, VT). Human
dansyl-Glu-Gly-Arg-chloromethylketone (DEGR-Xa) was pur-
chased from Hematologic Technologies Inc. All of the phos-* This work was supported, in whole or in part, by National Institutes of Health
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pholipids were obtained from Avanti Polar Lipids (Alabaster,
AL). 1,2-Dihexanoyl-sn-glycero-3-phospho-D-serine was cus-
tom synthesized by Avanti Polar Lipids (Alabaster, AL). The
fluorescent probe 1-[4 (trimethylammonium)-6-phenyl]-1,3,5-
hexatriene (TMA-DPH) was obtained from Molecular Probes
(Eugene, OR). Chromogenic substrates were from Chromoge-
nix (Molndal, Sweden). Cell culture media were from Invitro-
gen (Carlsbad, CA).
Recombinant Proteins—Native recombinant factor Va2
(rHFVa)was expressed inCOS-7 and purified using established
methods (11).
Phospholipid Preparations—Phospholipid (both synthetic
and natural) vesicles were prepared by sonication as previously
described (11). Measured suspensions of C6PS and C6PE were
prepared as previously described (12).
Prothrombinase Assay—Rates of thrombin generation were
determined in reaction mixtures containing factor Va, factor
Xa, 1.4 M prothrombin, and phospholipid vesicles in 25 mM
Tris, pH 7.4, 150 mM NaCl, 2.7 mM KCl, 10 mg/ml BSA, and 3
mMCaCl2. Experiments were performed using either all bovine
coagulation proteins or all human coagulation proteins. Rates
of thrombin generation were measured using the substrate
S2238 as described previously (11). Thrombin generation was
also assayed in some cases usingDAPAexactly as described (12)
in the presence of 3 mM CaCl2.
Membrane Binding of Factors Xa and Va—Fluorescence
energy transfer from Trp to a membrane-located dansyl probe
was measured using either an SLM-8100 or a SPEX Fluoro-
Log-3 fluorescence spectrophotometer, as described by Gilbert
et al. (13) and modified by Peng et al. (11).
Binding of Factors Xa and Va to Soluble Lipids—A SPEX
FluoroLog-3 spectrofluorometer (Horiba Jobin Yvon Inc., Edi-
son, NJ) was used to measure intrinsic fluorescence intensity,
using an excitationwavelength of 280 nm (4-nmband pass) and
an emission wavelength of 340 nm (4-nm band pass) as
described previously (14). In dual-ligand experiments, human
factor Xa and rHFVawere preincubatedwithC6PS at 23 °C and
then titrated with C6PE and vice versa. Fluorescence data were
fit to a single-site binding model using aMarquardt-Levenberg
algorithm (14).
Interfacial Packing: TMA-DPH Fluorescence Anisotropy—
TMA-DPH was incorporated into membranes by adding a
small volume (0.04–0.08% of vesicle sample volumes) of TMA-
DPH in methanol to vesicle suspensions to a final lipid:probe
ratio of 200:1. Fluorescence anisotropy was recorded after the
fluorescence signal stabilized (excitation wavelength, 360 nm;
emission wavelength, 450 nm) (15).
RESULTS
Prothrombinase Activity on PE Membranes—Previous stud-
ies reported that PE:PC membranes have either limited or no
capacity to promote formation of an active prothrombinase
complex (16).We recorded the activity of the bovine prothrom-
binase complex onDOPE:DOPCmembranes in the presence of
varying factor Va concentrations, 0.2 nM factor Xa, 1.4 M pro-
thrombin, 3 mMCaCl2, and 5 M phospholipid vesicles. Fig. 1A
shows that membranes containing 10–30% PE, 90–70% PC,
and no PS supported prothrombinase complex activity. Activ-
FIGURE 1. Prothrombinase activity on DOPC:DOPE:DOPS membranes.
A, rates of thrombin generation were determined at 37 °C in reaction mixtures
containing 25 mM Tris, pH 7.4, 150 mM NaCl, 2.7 mM KCl, 0.6% PEG 8000, 3 mM
CaCl2, 0.2 nM bovine factor Xa, a fixed concentration of prothrombin (1.4 M),
varying factor Va concentrations, and 5 M of DOPC:DOPE vesicles of varying
compositions: 70:30 (E), 80:20 (), and 90:10 (ƒ). Three independent exper-
iments are shown for each phospholipid vesicle composition. The line repre-
sents global fitting (GraphPad Prism) of the data while varying parameters
Kd
app and Vsat, as described under “Experimental Procedures.” The inset shows
the rates of thrombin formation in the presence of 30% egg PE:70% egg PC
membranes. B, binding of DEGR-Xa to factor Va2 in the presence of 30:70
DOPE:DOPC membranes was determined in the presence of increasing con-
centration of factor Va2 and at a fixed concentration of DEGR-Xa (10 nM). The
buffer was same as in A. The line represents the best fit of the data to a simple
single-site binding model as obtained using Sigma Plot. C, rates of thrombin
generation were determined at 37 °C in reaction mixtures containing 3 mM
CaCl2, 0.2 nM bovine factor Xa, 5 nM bovine factor Va, 5 M of vesicles of
varying compositions: 100% DOPC (F), 80:20 DOPC:DOPE (Œ), 69:30:1, and
DOPC:DOPE:DOPS (f). The lines show the fit of these data using Sigma Plot to
a standard Michaelis-Menten model to determine the kcat and Km of pro-
thrombin activation with membranes of different lipid compositions, as
described in the text.
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ity increasedwith increasingDOPEmembrane content and sat-
urated at high factor Va (Vsat), indicating that activity reflects
formation of a Xa-Va complex on PE:PC membranes, with a
Kdapp of 0.8 0.1 nM on 30%PEmembranes. The effect of DOPE
on Vsat was optimal by 20% DOPE and, Kdapp for prothrombi-
nase formation at 30% DOPE was comparable with values
reported for prothrombinase formation on PS-containing
membranes (17). For this reason and because the PE content of
platelet microparticles or platelet membranes is roughly 30%
(18, 19), our focus will be on membranes containing 30% PE.
Membrane mimetic phospholipid vesicles have been used to
model the assembly and activity of the prothrombinase com-
plex on platelet membranes. Researchers have used synthetic
lipids (16, 20), as well as lipids derived from natural sources (21,
22). In our work, we use synthetic lipids because they are chem-
ically more stable. In control experiments, we investigated the
activity of the prothrombinase complex assembled on phos-
pholipid membranes composed of 70 or 80% egg PC and 20 or
30% egg PE to ensure that our results are not artifacts associated
with a particular synthetic lipid species. Nearly identical results
were obtained with membranes containing egg yolk-derived
lipid (Vsat  245  25 IIa min1 and Kdapp  0.7  0.2 nM for
30% egg PE, as shown in Fig. 1A, inset) and with DOPE:DOPC-
containing membranes (Table 1 and Fig. 1A).
Our smallKdapp is consistent with that reported by Smirnov et
al. (10), who interpreted this as the Kd for assembly of the pro-
thrombinase complex. To confirm this interpretation, the fluo-
rescence of DEGR-FXa in the presence of 30% DOPE:DOPC
membranes was recorded (23) (Fig. 1B) to obtain the Kd for
association of factors Va and Xa (2  0.4 nM). This was compa-
rable with the Kdapp recorded in Table 1, confirming that the
Kdapp values do reflect assembly of the Xa-Va complex on
DOPC:DOPE membranes.
Because previous studies (10) focused only on PE effects on
Km and not on kcat, we determined the initial rates of thrombin
generation in the presence of pure DOPC or DOPC:DOPE (70:
30) membranes, 0.2 nM Xa, 5 nM Va, and increasing concentra-
tions of prothrombin (0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, and 2M)
(Fig. 1C). Fitting these data resulted in a Km of 0.43  0.02 M
for 70:30 DOPC:DOPE membranes, which is 15-fold lower
than for DOPC membranes (Kmapp  6  1 M; data not
shown). We note that prothrombinase activity did not saturate
with respect to Va addition for DOPC membranes because Va
binds very weakly to such membranes (24). The kcat for throm-
bin generation obtained with DOPC membrane was only
0.08  0.01 s1, compared with 21.5  2 s1 for 70:30 DOPC:
DOPE membranes, nearly a 28-fold increase caused by the
presence of DOPE. Overall, the kcat/Km for 70:30 DOPC:DOPE
membranes (5  107 M1 s1) was approximately that
reported for bovine Va-Xa complex on 25:75 PS:PC mem-
branes (17, 25). The rate of thrombin generation in the absence
of any lipid was not measurable in our reaction condition (0.2
nM FXa, 5 nM FVa2). Thus, the effect of DOPE on kcat was
comparable with, if not larger than, the effect on Km. This is
significant because a kcat effect implies a change in enzyme con-
formation, whereas a Km effect could reflect substrate binding
to the membrane-bound complex, which may or may not
reflect changes in enzyme structure. Including 1% DOPS in
DOPC:DOPEmembranes (69:30:1) (Fig. 2A) produced an iden-
tical Km (0.40  0.03 M) and a 2-fold increase in kcat (43.5  3
s1). This effect is seen in the Vsat values collected in Table 1,
FIGURE 2. DOPE enhances prothrombinase activity on membranes con-
taining low concentrations of DOPS. Rates of thrombin generation were
determined at 37 °C in buffer containing 25 mM Tris, pH 7.4, 150 mM NaCl, 2.7
mM KCl, 10 mg/ml BSA, 3 mM CaCl2, 0.2 nM bovine factor Xa, 1.4 M bovine
prothrombin, bovine factor Va, and 5 M DOPC:DOPS:DOPE vesicles of vary-
ing compositions: 69:1:30 and 99:1:0 (A), 65:5:30 and 95:5:0 (B), and 60:10:30
and 90:10:0 (C). In A, four independent experiments are shown. Global fitting
of the data for Vsat and Kd
app was performed using GraphPad Prism version
4.00. In B and C, the error bars represent one standard error of the parameter
for triplicate measurements in a representative experiment.
TABLE 1
Contribution of PS, PE, and DPhPC to prothrombinase activity
Rates of prothrombin activation were determined on phospholipid vesicles with the
compositions specified using bovine coagulation proteins as described under
“Experimental Procedures.” The parametersKdapp andVsat for prothrombinase com-
plex formation (Fig. 1) are expressed as the means  S.E. of the parameter, where
standard errors are derived from fitting a single experiment or globally fitting N
independent experiments to a hyperbola (see “Experimental Procedures”). ND, not
detected.
Membrane Kdapp Vsat N
nM nMmin1
DOPC:DOPE
90:10 12  4 127  22 3
80:20 9.8  1.5 246  18 3
70:30 0.8  0.1 234  5 3
DOPC:DOPS
99:1 17  8 8  3 3
95:5 1.1  0.2 629  26 3
90:10 0.2  0.0 675  10 3
75:25 0.3  0.1 800  30 1
DOPC:DOPE:DOPS
69:30:1 1.3  0.2 459  15 4
65:30:5 0.3  0.0 754  15 6
60:30:10 0.3  0.1 762  21 1
DOPC:DPhPC:DOPS
70:30:0 30  4 0.8  0.1 2
69:30:1 1.3  0.4 7.9  0.6 3
65:30:5 0.3  0.0 643  14 1
60:30:10 0.3  0.0 685  14 1
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where we see that additional membrane DOPS content led to
only a small further increased activity (2-fold). This small
amount of PS also reduced Kdapp (Table 1 and Fig. 2A). Addi-
tional PS (5–10%) roughly doubled Vsat (Table 1 and Fig. 2, B
and C), meaning that only 1% PS is needed to form a nearly
optimal prothrombinase in the presence of 30% PE. The exper-
iments summarized in Table 1 were all carried out with 1.4 M
prothrombin, which is well above the Km for prothrombinase
on 30% DOPE vesicles with or without 1% PS. Because PS had
no measurable effect on Km for membranes containing 30%
DOPE, we conclude that the increase in saturating activity
(Vmax) with increasing PS is due to increases in kcat.
From the results summarized inTable 1, it is clear thatDOPE
significantly promoted prothrombinase complex assembly and
activity only for membranes containing little or no DOPS,
whereas DOPE had little effect when incorporated into mem-
branes containing 5% DOPS, in agreement with Smirnov et
al. (10). However, the current results establish that PE also
increases kcat and that PS further increases both kcat and Kdapp
but not Km.
Because of the expense of isolating human factor Va and
because many earlier experiments used bovine factor Va (26),
bovine coagulation proteins were used in most of these exper-
iments. However, control experiments using human coagula-
tion proteins confirmed that similar kinetics are seen for
human prothrombinase assembled on 70:30 DOPC:DOPE
membranes (kcat  12  2 s1, Km  0.6  0.04 M, and kcat/
Km  2  107 M1 s1) as we found using bovine proteins.
Binding of Factor Va to PE Membranes—We used intrinsic
fluorescence to follow the binding of bovine factor Va to mem-
branes containing variable concentrations of DOPE and DOPS
(Fig. 3 and Table 2). Surprisingly, factor Va bound fairly tightly
tomembranes containing only 30% (Kd  10 3 nM; Fig. 3A) or
20%DOPE (Kd  12 8 nM) butmoreweakly (Kd  51 8 nM)
to membranes containing only 10% DOPE (Table 2). Bovine
factor Va interacts extremely weakly (Kd  3 M) with mem-
branes composed of only egg PC (24), demonstrating that even
a small fraction of PE is very important for factor Vamembrane
binding. Factor Va bound similarly but somewhat more tightly
to 30% PEmembranes composed of highly unsaturated natural
egg yolk-derived lipids (Fig. 3A, inset; Kd  3  0.5 nM) com-
pared with the synthetic lipids used in this study. This is con-
sistent with the observation that factor Va binding free energy
derives principally from insertion of Trp residues into the
membrane (27), an event that should be promoted by the
reduced interfacial packing associated with highly unsaturated
lipids. Adding 1% PS to 30% DOPEmembranes had little effect
on factor Va binding, although increasing PS content to 5–10%
did improve binding somewhat but not beyond what was
observed in the absence of DOPE (Table 2). We conclude that
although PE does promote Va binding to membranes, PS pro-
motes tighter binding in a PE-independent fashion. As a con-
trol, we showed that the Kd for bovine Va binding to 75:25
DOPC:DOPS membranes (0.35 nM) (Table 2) was comparable
with that reported for human recombinant factor Va to syn-
thetic vesicles (Kd  0.24 nM) (28), indicating that our results
are not species-specific.
Although addition of 1% DOPS to membranes containing
30% DOPE decreased Kd, it simultaneously increased the stoi-
chiometry of binding (number of lipids per bound protein at
saturation), such that the combined effect of 30% DOPE and
DOPS was roughly that of DOPS alone. Even at 1% DOPS, the
addition of 30% DOPE had little effect on Va binding (Kd for
binding to 1% DOPS decreased only from 17  8 to 9  5 nM
with inclusion of 30%DOPE; Fig. 3B andTable 2).We conclude
that there is minimal synergistic effect of DOPE and DOPS on
factor Va membrane binding, even at very low DOPS content.
Effects of Interfacial Packing on Prothrombinase Activity and
Factor Va Binding—PE can adopt a nonlamellar, reverse hex-
agonal (HII) phase because it has a small head group and two
acyl chains (29, 30). Because the HII phase has negative curva-
ture with respect to its symmetry axis, PE is said to have a
negative “intrinsic membrane curvature” and can induce cur-
FIGURE 3. Binding of factor Va to phospholipid vesicles. Samples con-
tained 150 mM NaCl, 20 mM Tris, pH 7.4, and 0.6 M labeled DOPC:DOPS:DOPE:
dansyl-PE vesicles of varying compositions: 70:0:27.5:2.5 (A), 69:1:27.5:2.5 and
96.5:1:0:2.5 (B), 65:5:27.5:2.5 and 92.5:5:0:2.5 (C), and 60:10:27.5:2.5 and 87.5:
10:0:2.5 (D). Fluorescence measurements (F) were made as described under
“Experimental Procedures” after incremental addition of bovine factor Va at
25 °C. The lines represent the best fit of data in one representative experi-
ment. The inset in A shows the binding of bovine Va to egg PE:egg PC (20:80)
membranes.
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vature elastic stress in a monolayer, such that packing in the
interface of that monolayer is reduced, especially for unsatu-
rated acyl chains and/or high temperature (31). Although this
effect actually depends on the other lipids present in themono-
layer, it is commonly assumed for convenience that monolayer
curvature is an additive property of the intrinsic curvatures of
all lipids in the monolayer (31). Based on the assumption of
intrinsic curvature additivity, it was proposed that the stimula-
tory effect of PE on prothrombinase caused by its molecular
shape should reduce membrane surface packing (10).
To test this proposal, we constructedmodelmembranes hav-
ing experimentally defined relative interfacial packing and con-
taining defined amounts of DOPC, DOPE, and DOPS. To
adjust measured interfacial packing, we used another synthetic
phospholipid, 1,2-diphytanoyl-sn-glycero-3-phosphocholine
(DPhPC), also shown to induce HII phase and having a cross-
sectional area ratio of lipid head groups to acyl chains similar to
DOPE (32). UnlikeDOPE,which has a head groupwith reduced
cross-sectional area, DPhPC derives its thermal shape from
very bulky acyl chains. We use changes in TMA-DPH fluores-
cence anisotropy, previously shown to report changes in inter-
facial order in outer monolayers of membranes to which it
absorbs (33, 34), to reflect differences in interfacial order
between membranes.
Our results demonstrate that both PS and PE promote pro-
thrombinase activity but that there is no correlation between
membrane interfacial order, as detected using an established
probe of interfacial order, and increased activity.We designed a
PS-free composition by a combination of rational design and
trial and error (DOPC:DPhPC:DOPE, 65:5:30) having the same
interfacial order as pure DOPC membranes. Membranes with
this composition supported significantly more activity than
pureDOPCmembranes (Table 3), demonstrating a PE-induced
activity increase without a decrease in surface packing. Adding
just 1% DOPS to these membranes reduced interfacial order
substantially (Table 3), demonstrating that in this model mem-
brane system, monolayer intrinsic curvature indeed cannot be
approximated as an additive function of composition. The
addition of this small amount of DOPS also increased activity
roughly 9-fold. Although DPhPC increased interfacial order in
PS-free vesicles, the addition of 1% DOPS produced a dramatic
decrease in order, but still only a 10-fold increase in activity
(Table 3). These activity increases are comparable with that
seen for adding 1% DOPS to pure DOPCmembranes (Table 3)
and thus are likely effects of DOPS, not of bilayer packing
changes. By contrast, the addition of 30% DOPE to DOPC
membranes produced only a small decrease in packing (Table
3) but a 600-fold increase in activity.
In contrast to activity, Table 3 demonstrates that a reduction
inmembrane packing did enhance factorVa binding. If reduced
membrane packing can promote factor Va binding, could it be
that PE also promotes factor Xa binding, thereby helping to
bring both to the surface of a 30% PE membrane to promote
prothrombinase assembly?
Factor Xa Binding to PE Membranes—Using concentrations
of bovine factor Xa up to 1 M and our FRET binding assay, we
were unable to obtain reliable Xa binding data withmembranes
containing 30%DOPE or 25%DOPS. The latter result is con-
sistent with previous reports (Kd of 1.5 M for 10% bovine
brain PSmembranes) (8). However, the presence of 30% DOPE
increased the affinity of factor Xa for membranes containing
10% PS (Kd  187 nM), similar to the value for binding to
75:25 DOPC:DOPSmembranes (Kd  219 nM), which is con-
sistent with previous Kd estimates for 25% PS membranes (8,
25). These observations suggest that 30% DOPE in membranes
containing less than optimal DOPS might enhance factor Xa
binding slightly but likely not sufficiently to explain the dem-
onstrated prothrombinase supporting ability of 30% DOPE
membranes (Fig. 2). Next, we consider another possible expla-
nation, specific binding of PE to either factor Xa or Va to trigger
changes in these proteins that might increase factor Xa activity
or enhance formation of a prothrombinase complex.
TABLE 2
Contribution of PS, PE, and DPhPC to binding of bovine factor Va to
membranes
The binding of bovine factor Va to phospholipid vesicles with the compositions
specified was analyzed as described under “Experimental Procedures.” The param-
etersKd, n, and (F∞/Fb) 1 were calculated by fitting the data as shown in Fig. 3.Kd,
dissociation constant for factor Va binding to phospholipid vesicles; n, number of
phospholipid monomers composing a single binding site; N, number of indepen-
dent experiments; ND, no measurable binding detected.
Membrane Kd n N
nM
DOPC:DOPE
90:10 51  8 21  27 2
80:20 12  8 20  4 3
70:30 10  3 22  3 2
DOPC:DOPS
99:1 17  8 a 2
95:5 2.3  0.3 136  9 2
90:10 1.4  0.2 74  3 4
75:25 0.35  0.17 51  2 2
DOPC:DOPE:DOPS
69:30:1 9  5 36  12 2
65:30:5 1.9  0.3 93  7 4
60:30:10 1.3  0.3 69  5 2
DOPC:DPhPC:DOPS
70:30:0 ND ND 2
69:30:1 7  3 85  34 2
65:30:5 3.4  0.8 101  14 2
60:30:10 1.6  0.2 63  2 3
a The value for n did not converge.
TABLE 3
Interfacial packing of factor Xa activity on and factor Va binding to vesicles containing different concentration of DOPC and DOPE and in the
absence and presence of 1% DOPS
0% DOPS 1% DOPC replaced by 1% DOPS
Lipids TMA-DPH Anisotropy Activity Vsat Va Binding TMA-DPH Anisotropy Activity Vsat Va Binding
nM/min nM nM/min nM
100% PC 0.2271 0.6  0.1 ND 0.2231 8  3 17  8
70% PC  30% PE 0.2119 234  5 10  3 0.2007 459  15 9  5
65% PC  5% DPhPC  30% PE 0.2242 52  4 6350  700 0.2036 486  12 10  2
70% PC  30% DPhPC 0.2416 0.8  0.2 ND 0.1948 7.9  0.6 7  3
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Soluble C6PE Binds to rHFVa and Factor Xa—Because of the
large effect of PE on kcat, we hypothesized that PEmight bind to
regulatory sights on either factor Xa or factor Va, as we have
documented for PS binding to these proteins (12, 35, 36). To
investigate this, direct binding of C6PE to rHFVa2 was exam-
ined bymeasuring changes in intrinsic fluorescence as reported
previously (36). We utilized only the factor Va2 glycoform
because we showed that soluble PS does not stimulate forma-
tion of an active prothrombinase complex from the Va1 glyco-
form (23). We determined at each experimental condition the
critical micelle concentration of C6PE (12) to confirm the
absence of C6PE micelles. The critical micelle concentrations
of C6PE in the presence of 100 nMhuman rHFVa2 and factorXa
were 800 and 850M, respectively. C6PE bound to rHFVa2with
a Kd of 6.5  0.5 M based on a single-site model for binding
(Fig. 4A), comparable with values previously reported for C6PS
binding to rHFVa2 (20 M) (14). Interspecies control experi-
ments confirmed that C6PE bound with affinity comparable
with that of bovine Va2 (shown in the inset to Fig. 4A; Kd  8
M) and also comparablewithC6PSbinding to bovine factorVa
(9 M) (36).
We also used intrinsic fluorescence to detect binding of
C6PE to human factor Xa (Fig. 4B) and bovine factor Xa (Fig.
4B, inset). When analyzed using a single-site model, these data
yielded Kd values of 91  13 and 90  10 M, respectively, also
comparable with previously reported values for C6PS binding
(73–90 M) (35, 37).
To test directly whether PE binding promotes assembly of
the Xa-rHVa2 complex, binding of DEGR-Xa to rHVa2 in the
presence of 400 M C6PE was monitored by following
DEGR-Xa fluorescence (23), as shown in Fig. 4C. The titration
curve was well described by a single-binding site model with a
dissociation constant Kd Va-Xa,  40  3 nM for assembly of the
Xa-Va2 complex. This is 20-fold weaker than for assembly in
the presence of C6PS (2 nM at 22 °C) (12) but 25-fold tighter
than estimated for assembly in the absence of lipid (1 M)
(12). A factor of 25 in binding affinity corresponds to a free
energy of interaction that ismore favorable by3 kBT. This is a
very significant free energy change for a two-dimensional bind-
ing reaction at lowmembrane concentration. Thus, theKdapp for
prothrombinase assembly for 5 M 30:70 DOPE:DOPC mem-
branes ( 0.8 nM; Table 1) is much smaller than for DOPC
membranes, for which prothrombinase assembly was unde-
tectable (data not shown).
Synergy between Binding of C6PS and C6PE to Human Fac-
tors Xa and rHFVa—Our results and those of others (38) dem-
onstrate synergy between PE and PS in membranes. In experi-
ments analogous to those reported in Fig. 4, we recorded at
increasing C6PS concentrations (0–200 M) the intrinsic fluo-
rescence intensity of 0.1 M human factor Xa preincubated for
15 min with a saturating concentration of C6PE. The data were
again appropriately analyzed according to a single-binding site
model to obtain an apparent Kd of 40  5 M for C6PS binding
in the presence of 200 M C6PE (Table 4). Similarly, we
obtained the apparent Kd of C6PE binding to human factor Xa
preincubatedwith a saturating concentration of C6PS (400M)
(Kd  7  0.7 M; Table 4). The results summarized in Table 4
clearly indicate synergy between C6PS and C6PE binding to
factor Xa. To determine whether this effect was specific for the
PE species, we tested whether C6(D)PS or C6PC binding was
similarly linked to C6PS binding. The results in Table 4 show
clearly that preincubating with these lipids did not alter the
affinity of C6PS for factor Xa, nor did preincubating with C6PS
alter the affinity for C6(D)PS or C6PC (Table 4). We conclude
that the synergy betweenC6PS andC6PEbinding to factorXa is
FIGURE 4. Binding of rHFVa and Factor Xa to soluble C6PE. The intrinsic
fluorescence intensity of 0.1 M rHFVa (A) or 0.1 M human factor Xa (B) in
20 mM Tris, 150 mM NaCl, and 5 mM CaCl2, pH 7.5, was measured as a
function of C6PE concentration at 23 °C. The data were analyzed accord-
ing to a simple single-binding site model to yield a Kd of 6.5  0.5 M for
rHFVa and 91  1.4 M for factor Xa. The insets to A and B show the binding
of bovine factors Va/Xa with C6PE (Kd values are 8  1.2 and 90  14 M for
factors Va and Xa, respectively). C presents fluorescence of DEGR-Xa with
the addition of rHVa2 in the presence of 400 M C6PE. The fit of a single-
binding site model to the data provided the Kd (40  3 nM) for Xa-DEGR-
Va2 complex formation.
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specific for these lipids. Synergy between C6PS and C6PE bind-
ing to 0.1 M rHFVa was not observed (Table 4).
DISCUSSION
Earlier studies (9, 10, 16) found that PE was synergistic with
PS in enhancing prothrombinase activity on membranes con-
taining low concentrations of PS. Smirnov et al. (10) focused on
the effect of PS on Km for prothrombin activation and the Kdapp
for Va-Xa assembly at high (50%) surface concentrations of PE.
They had reported that 50% PE promoted prothrombin activa-
tion only onmembranes having 0 or 1%PS and that the effect of
50% PE alone was only 15% of that for PE with any amount of
PS, i.e. that the effect of PE on prothrombinase activity was
much less than the effect of PS. We report that 30% DOPE
membranes are surprisingly35% as active asmembranes con-
taining 30% DOPE and 10% DOPS, roughly the proportion of
these species exposed on activated plateletmembranes (18, 19),
making it important to understand the mechanism for PE and
the ability of PE both to promote prothrombinase assembly and
activity, both synergistically with PS and in the absence of PS. In
this regard, Smirnov et al. (10) hypothesized that the effects of
PE on prothrombinase assembly and activity might be due to
reduced interfacial packing expected for membranes contain-
ing PE. The present study was designed to test this hypothesis
and thereby define themechanism by which the presence of PE
in a membrane enhanced prothrombin activation by mem-
brane-bound factors Va and Xa.
We report seven significant new observations: 1) PE effects
kcat more thanKm (Fig. 1C), and a kcat effect strongly implies an
enzymeor cofactor conformational change,whereas aKm effect
could be due to conformational changes or to altered binding of
enzyme cofactor and substrate to the membrane; 2) PE pro-
motes binding of factor Va to membranes (Fig. 3 and Table 2),
and because we showed that reduced membrane packing
enhanced factor Va binding, the effect of PE on Va binding is
probably due to its ability to reduce membrane packing; 3) PE
promotes assembly of a prothrombinase complex (Fig. 1,A and
B) because of its effects on factorsVa andXa independent of the
presence of a membrane (Fig. 4C) and thus not because of its
effects on membrane packing; 4) 30% PE does not produce a
measurable effect on factorXamembrane binding; 5) C6PE and
C6PS bind synergistically to sites on factor Xa to alter its activ-
ity (Table 4); 6) C6PE binds to factor Va with greater affinity
than does C6PS, but binding of these lipids to sites on this
protein is not synergistic (Table 4); and 7) both PS and PE pro-
mote prothrombinase activity, but the magnitudes of these
effects do not correlate with their effects onmembrane interfa-
cial packing (Table 3).
All of these observations are consistent with a new hypothe-
sis for how PE promotes prothrombin activation. First, factor
Va binds with significant affinity to 30% PE membranes (Table
2) because its membrane-binding free energy derives almost
exclusively from penetration of the membrane interface by two
Trp residues (39). Even though factor Xa binds poorly to 30%
DOPE membranes, once a small amount of Xa binds to the
membrane, PE will occupy regulatory sites on it and factor Va,
resulting in formation of an active prothrombinase complex.
Because C6PS is more effective than C6PE in increasing factor
Xa activity and in promoting Xa-Va interaction (Fig. 4), even a
small amount of PS in the 30% DOPE membrane will occupy
the regulatory sites on Xa and Va to increase in Vsat and
decrease in Kdapp (Table 1). Even though prothrombin does not
bind tightly to a 30% PE membrane, the well known reduction
of Km upon binding to PS-containing membranes is due to
binding of lipids to the regulatory site on Xa and not to the
availability of membrane-associated prothrombin (40). In this
picture, the effect of PE on membrane interfacial packing con-
tributes only to bringing factor Va to themembrane, but not for
the reduction in Km, the increase in kcat, and the decrease in
Kdapp, which result fromPE regulation of both factorsXa andVa.
The lipid-binding regions through which C6PS influences
factorsVa andXahave been identified (14, 27, 41). Are these the
same sites occupied by PE? Although we cannot say with cer-
tainty, our data suggest that this is the case for factor Xa. The
initial rate of factor Xa-mediated prothrombin activation
increased by 4-fold in the presence of saturating (400M)C6PE
(data not shown). A subsaturating concentration of C6PS (50
M) produced a 15-fold activity increase, whereas subsequent
addition of a saturating concentration (400 M) of C6PE
increased factor Xa activity by an additional 2.7-fold (total
40-fold increase, as compared with no lipid). This effect is less
than the 60-fold increase seen with C6PS alone (37). This is
consistent with C6PE and C6PS competing for common sites,
because the addition of C6PEwould displace C6PS, resulting in
decreased activity. If these lipids bound two different sites, we
would expect a 4  15  60-fold) change, which was not
observed. However, why do we observe synergy in Kd values if
the two lipids have common sites? This could be explained by
C6PE binding to two linked sites, as has been reported for C6PS
(41). Our current hypothesis is that C6PS and C6PE share the
regulatory site on Xa (non-additive effects on activity) but also
bind to the anomalous site in the catalytic domain to which the
regulatory site is linked (41). More extensive experiments are
needed to prove this hypothesis. We expect that this is not the
case for factor Va2, because only the site in the C1 domain
regulates the interaction between factors Xa and Va (27). We
TABLE 4
Linkage between sites for C6PS and C6PE on human factors Xa and
rHFVa2
Binding of soluble phospholipids to 0.1 M rHFVa or 0.1 M human factor Xa was
monitored using intrinsic fluorescence intensity in 20mMTris, 150mMNaCl, and 5
mMCaCl2, pH 7.5, as a function of C6PS, C6PE, C6PC, or C6(D)PS and the concen-
tration at 23 °C. The data were analyzed according to a single binding site model to
reveal the effects of preincubationwith one lipidC6PE orC6PS on the binding of the
other.
Protein Lipid titrant Conditions Kd
M
Xa C6PS No other lipid 86  10 (35)
C6PS Preincubated with 200 M C6PE 40  5
C6PS Preincubated with 400 M C6(D)PS 95  12
C6PS Preincubated with 400 M C6PC 90  8
Xa C6PE No other lipid 91  13
C6PE Preincubated with 400 M C6PS 7  0.7
Xa C6(D)PS No other lipid 71 (35)
C6(D)PS Preincubated with 400 M C6PS 67  24
Xa C6PC No other lipid 203  27 (35)
C6PC Preincubated with 400 M C6PS 198  68
Va C6PS No other lipid 20  1 (14)
C6PS Preincubated with 200 M C6PE 17  3
Va C6PE No other lipid 6.5  0.5
Preincubated with 400 M C6PS 5.6  0.5
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will need additional studies to confirm that this site also binds
C6PE to regulate assembly.
The effects of PE in model membrane studies are insignifi-
cant for membranes containing 1% PS (our results and Ref.
10). Platelet activation is generally recognized to expose plasma
to membranes containing upwards of 11–13% PS and 25–35%
PE (18). If we view coagulation in terms of the four stages (ini-
tiation, amplification, propagation, and shutdown) proposed in
the emerging cell basedmodel (42), our results make it unlikely
that PE plays a significant role during the propagation stage, at
which point platelet activation has already occurred. However,
during initiation and perhaps the early part of amplification,
our results show that the small amount (10 mol%) of PE
exposed on resting platelets along with the even smaller
amount of PS (1–2 mol%) could promote formation of pro-
thrombinase if factors Xa and Va were available. Because small
amounts of these proteins are produced via the TF-VIIa reac-
tions at the earliest stages of platelet plug formation, they could
assemble an active prothrombinase on unactivated platelets
and trigger formation of sufficient thrombin to activate more
platelets and initiate the amplification stage.
Even in the absence of PS, we show thatmembranes contain-
ing 30% PE are remarkably effective in assembling an active
prothrombinase reaction. This is particularly interesting in
light of the report that very LDLs promote prothrombin activa-
tion even though they contain essentially no PS (43). Evenmore
interesting is the report that oxidized LDL particles, even
though they contain no PS, elicit a strong prothrombin activat-
ing activity, likely because of small amounts of PE oxidation
products that resemble PS (44). Thus, our results are consistent
with the possibility that PE plays an important role in the etiol-
ogy of atherosclerotic lesion-induced clot formation.
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